TP53 and central nervous system cancer: Even though in gliomas mutations in IDH1 and IDH2 genes are usually heterozygous, homozygous ones also exist. IDH1/IDH2 aberrations, but not the ones in TP53, together with age might be applied in clinical practice for prediction of survival in patients with glioblastomas.